Treatment
Cell clinical trials
We’re tracking 5,684 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT06153173RecruitingPhase 2
Mirdametinib for histiocytic disorders
This trial tests a drug called mirdametinib for people with histiocytic disorders, which are rare diseases where certain immune cells grow out of control. It may help shrink tumors and improve symptoms when other treatments haven't worked.
Cincinnati, OhioAges 2 years+ - NCT06154668Recruiting
Immune cell study in melanoma patients
This study looks at immune cells in your blood to find patterns that might show how well a treatment called anti-PD1 immunotherapy works for melanoma. Your participation could help doctors better understand who benefits from this therapy.
GrenobleAges 18 years+ - NCT06154915Recruiting
Immune cells in diabetic foot ulcers
This study looks at immune cells in chronic foot ulcers caused by diabetes. It may help researchers understand how these ulcers heal, which could lead to better treatments.
Huddinge, Stockholm CountyAges 18–98 - NCT06155266Recruiting
Blood test to tell bacterial vs viral infection
This trial uses a simple blood test to help doctors quickly tell if your infection is caused by bacteria or a virus. It only requires a small extra blood sample taken during your regular emergency visit.
ParisAges 18 years+ - NCT06155188Recruiting
New transplant method for childhood leukemia
This study tests a new combination of medicines to help donor cord blood cells grow better in children with leukemia after a transplant.
Guangzhou, GuangdongAges 1 month–18 years - NCT06158386RecruitingPhase 2
Chidamide and linperlisib for relapsed follicular lymphoma
This trial tests a combination of two oral drugs, chidamide and linperlisib, for people with follicular lymphoma that has not responded to or come back after at least two prior treatments. The goal is to see if this combination can help shrink the lymphoma and stop it from growing.
Xiamen, FujianAges 18 years+ - NCT06158399RecruitingPhase 2
Combination therapy for a specific type of lymphoma
This trial tests a new drug combination (azacitidine plus standard chemotherapy) for people with a certain genetic subtype of diffuse large B-cell lymphoma (DLBCL) that has a mutation in the TP53 gene. It may offer a more targeted treatment option.
Xiamen, FujianAges 18–70 - NCT06160596Recruiting
Understanding long-term cancer survival in hard-to-treat tumors
This study looks at why some people with hard-to-treat cancers live much longer than expected. It collects tumor samples to search for clues that might help future patients.
VillejuifAges 18 years+ - NCT06161896Recruiting
Gut bacteria's role in lymphoma treatment
This study looks at the bacteria living in your gut (your gut microbiome) to see if they affect how well lymphoma responds to treatment. It involves collecting stool and blood samples before and during your standard R-CHOP chemotherapy.
Roskilde, Region SjællandAges 18 years+ - NCT06167512Recruiting
Study on kidney cell changes after severe injury
This study looks at how kidney cells change their energy use after a severe injury. It may help doctors understand and treat kidney damage in trauma patients.
Le Kremlin-BicêtreAges 18 years+ - NCT06167681RecruitingPhase 1/Phase 2
Cell Therapy NouvNeu001 for Parkinson's Disease
This trial tests a new cell therapy called NouvNeu001 for Parkinson's disease. It involves a one-time brain surgery to deliver the treatment, and researchers will check if it's safe and helps with symptoms.
Beijing, Beijing MunicipalityAges 50–75 - NCT06169163Recruiting
Breath test for esophageal squamous cell cancer
This study looks at chemicals in your breath to see if they can help detect a type of esophageal cancer (squamous cell carcinoma) early. You may join if you have untreated squamous cell esophageal cancer, or if you are having a routine endoscopy for stomach issues and your results are normal or show a benign condition.
London, Greater LondonAges 18–90 - NCT06170710RecruitingPhase 2
Immunotherapy after chemoradiation for high-risk head and neck cancer
This trial tests if adding immunotherapy after standard chemoradiation helps prevent cancer from returning in people with high-risk head and neck cancer. It is for those who have completed surgery and have certain high-risk features.
Beijing, Beijing MunicipalityAges 18–70 - NCT06173986RecruitingPhase 1/Phase 2
Immunotherapy plus chemoradiation for advanced esophageal cancer
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
ShanghaiAges 18–75 - NCT06174597RecruitingEarly Phase 1
Stem cells for critical limb ischemia treatment
This trial tests whether stem cells from umbilical cord arteries can help people with severe leg pain or ulcers due to blocked arteries. It is for those who cannot have surgery or other procedures.
Nanjing, JiangsuAges 18–80 - NCT06176729RecruitingPhase 2
Pola-R2 for older, less fit adults with new DLBCL
This trial tests a combination of three drugs (pola, Rituxan, and lenalidomide) for older adults (70+) with a common type of lymphoma (DLBCL) who are not well enough for standard chemotherapy. The goal is to see if this gentler treatment works well for patients who are less fit.
Beijing, Beijing MunicipalityAges 70 years+ - NCT06177353Recruiting
Immune study in recessive dystrophic epidermolysis bullosa and stem cells
This study looks at the immune system in people with recessive dystrophic epidermolysis bullosa (RDEB) and tests how placental stem cells affect immune cells in the lab. It aims to understand the disease better and explore potential treatments.
ParisAges 18–80 - NCT06177925RecruitingPhase 2
Immunotherapy plus chemoradiation for limited spread SCLC
This trial tests a combination of an immunotherapy drug (adebrelimab) plus standard chemotherapy and radiation for people with extensive-stage small cell lung cancer that has only spread to a few places. The goal is to see if this approach can help control the cancer better.
GuangzhouAges 18–75 - NCT06180005Recruiting
Lung cancer genetic drivers study at CRO Aviano
This study is looking at people with non-small cell lung cancer (NSCLC) to find certain genetic changes that drive the cancer. It may help doctors understand which treatments could work best for you.
Aviano, PordenoneAges Any age - NCT06183268Recruiting
Proton therapy for head and neck cancer skin side effects
This study looks at how proton therapy affects skin in people with head and neck cancer. It aims to better understand and manage skin reactions during treatment.
Knoxville, TennesseeAges 18 years+ - NCT06186609RecruitingPhase 2
PD-1 Inhibitor and Radiation for Elderly Esophageal Cancer
This trial tests whether combining a PD-1 inhibitor (a type of immunotherapy) with radiation therapy can help older adults (70+) with esophageal squamous cell cancer who cannot have surgery. The goal is to see if this treatment is safe and effective for those with limited options.
Nantong, JiangsuAges 70 years+ - NCT06187597RecruitingPhase 2
Toripalimab after chemoradiation for older esophageal cancer
This study tests whether adding a drug called toripalimab after standard chemoradiation can help older adults with esophageal cancer. The goal is to see if this treatment can keep the cancer from coming back after initial therapy.
Guangzhou, GuangdongAges 70–85 - NCT06188650Recruiting
New drug combo for advanced lung cancer after two treatments fail
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
Ningbo, ZhejiangAges 18 years+ - NCT06190210Recruiting
Brain blood flow study in infants with heart defects
This study measures how well blood flows to the brain in infants with serious heart defects. The results may help doctors understand and protect brain development before and after heart surgery.
Leuven, Vlaams-BrabantAges Up to 6 months
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,684 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.